fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Rilpivirine hydrochloride

All products: general benefit

Edurant · DIN 02370603 · 25 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Edurant · DIN 02370603 Manufacturer: Janssen Inc.; listing date 2012-07-27 Health Canada: Marketed since 2014-09-09 · brand EDURANT · ATC J05AG05 RILPIVIRINE · form Tablet · route Oral · ingredients RILPIVIRINE (RILPIVIRINE HYDROCHLORIDE) 25 MG · company Janssen inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Edurant: Formulary list price $17.75 per unit (the source does not state the unit; exact figure $17.7500). What the ministry pays, not the patient.

Ministry pays: $17.7500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02370603)

Source record
DIN 02370603: Edurant Raw flags: sec3=Y Item: 081800355; group id 107; item number 0189; lccId None; manufacturer id JAN Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $17.7500; ministry $17.7500 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02370603 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85574
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02370603
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J05A, J05AG): coverage varies; not interchangeable

  • Delavirdine (Rescriptor): general benefit
  • Doravirine (Pifeltro): general benefit
  • Efavirenz (Sustiva): general benefit, not a benefit
  • Etravirine (Intelence): general benefit
  • Nevirapine (Viramune XR): general benefit, not a benefit
  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit

48 more in the class list below

Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

DELAVIRDINE MESYLATE

· 1 products · General benefit · strengths: 100mg · Tab

DORAVIRINE

· 1 products · General benefit · strengths: 100mg · Tab

EFAVIRENZ

· 5 products · Listed, not a benefit (1), General benefit (4) · strengths: 600mg · Tab

ETRAVIRINE

· 2 products · General benefit · strengths: 100mg, 200mg · Tab

NEVIRAPINE

· 7 products · Listed, not a benefit (2), General benefit (5) · strengths: 400mg, 200mg · ER Tab, Tab

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: human immunodeficiency virus type 1
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, ETRAVIRINE DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE · General benefit 1 INDICATIONS SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen for: • the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) and with no known mutations associated with resistance to the individual components of SYMTUZA®. PM: https://pdf.hres.ca/dpd_pm/00069792.PDF; date March 07, 2018; DIN 02473720; fetched 2026-09-10 Product monograph ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE · General benefit 1 INDICATIONS GENVOYA (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg and with no known mutations associated with resistance to the individual components of GENVOYA. 1.1 Pediatrics Pediatrics (weighing ≥ 25 kg): The safety and efficacy in children weighing ≥ 25 kg are based on data from an open-label clinical study (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00062412.PDF; date November 27, 2015; DIN 02449498; fetched 2026-09-10 Product monograph ETRAVIRINE · General benefit 1 INDICATIONS INTELENCE® (etravirine), in combination with other antiretroviral agents, is indicated for: • the treatment of human immunodeficiency virus type 1 (HIV-1) infection in treatment- experienced adult and pediatric (from 6 to <18 years of age and weighing ≥30 kg) patients who have failed prior therapy and have HIV-1 strains resistant to multiple antiretroviral agents, including NNRTIs (see 4 DOSAGE AND ADMINISTRATION). PM: https://pdf.hres.ca/dpd_pm/00075096.PDF; date March 27, 2008; DIN 02306778; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS EDURANT® (rilpivirine), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment- naïve adult and pediatric patients 12 years of age and older (and weighing ≥35 kg) with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy. 1.1 Pediatrics Pediatrics (12 to <18 years of age and weighing at least 35 kg): The safety, efficacy and pharmacokinetics of Edurant has been established in antiretroviral treatment-naïve, HIV-1 infected pediatric subjects 12 to less than 18 years of age and weighing at least 35 kg (see 4.2 Recommended Dose and Dosage Adjustment, 10.3 Pharmacokinetics, Pediatrics and 14.1 Clinical Trials by Indication, Treatment-Naïve Pediatric Patients (12 years to less than 18 years of age)). Pediatrics (<12 years of age): Edurant is not recommended for patients less than 12 years of age (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics (>65 years of age): Clinical studies of Edurant did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from adult subjects <65 years… https://pdf.hres.ca/dpd_pm/00077884.PDF PM date: July 20, 2011 Source product: EDURANT; DIN 02370603; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.